Evaluation of PSA Blood Levels Prior to and After Digital Rectal Examination

Evaluation of PSA Blood Levels in Men on Active Surveillance and Men With Benign Prostatic Hyperplasia Prior to and After Digital Rectal Examination

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02747563

Enrollment

Registered

2016-04-21

Start date

2016-05-31

Completion date

2017-05-31

Last updated

2016-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

prostate cancer, PSA, digital rectal examination

Brief summary

Patients with know prostate cancer (PCa) under active surveillance and aged matched controls without evidence of PCa will have a PSA blood test prior to and following standardized digital rectal examination

Detailed description

Patients with know prostate cancer (PCa) under active surveillance (Gleason 6, PSA \< 10 ng/ml) and aged matched controls without evidence of PCa will have a PSA blood test prior to and following standardized digital rectal examination. The change of PSA will be evaluated.

Interventions

OTHERBlood test (PSA)

Measurement of blood PSA levels

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Males * Intact Rectum * Prostate Cancer eligible for active surveillance

Exclusion criteria

* Pror radiation therapy * Under Androgen Deprivation Therapy * Prior prostate surgery

Design outcomes

Primary

Measure	Time frame
Percentage of PSA elevation after DRE	1 hour

Countries

Israel

Contacts

Primary ContactUri Lindner, M.D.

urili@clalit.org.il

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026